These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Re: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Mayordomo JI; Rivera F; Diaz-Puente MT; Lianes P; Cortes-Funes H J Natl Cancer Inst; 1993 Aug; 85(15):1251-3. PubMed ID: 8331689 [No Abstract] [Full Text] [Related]
23. Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Hoekman K; Vermorken JB Ann Med; 1996 Apr; 28(2):175-82. PubMed ID: 8732647 [TBL] [Abstract][Full Text] [Related]
24. Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Garattini E; Gianni M; Terao M Curr Pharm Des; 2007; 13(13):1375-400. PubMed ID: 17506722 [TBL] [Abstract][Full Text] [Related]
25. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Miller WH Cancer; 1998 Oct; 83(8):1471-82. PubMed ID: 9781940 [TBL] [Abstract][Full Text] [Related]
26. Haemopoietic growth factors in oncology. Aglietta M; Pasquino P Pharmacol Res; 1992 Sep; 26 Suppl 2():80-1. PubMed ID: 1409332 [No Abstract] [Full Text] [Related]
27. [Use of hematopoietic growth factors in oncology]. Delmer A; Zittoun R Bull Cancer; 1991; 78(2):115-31. PubMed ID: 2036483 [TBL] [Abstract][Full Text] [Related]
28. High dose chemotherapy with haemopoietic support for breast cancer. Steward WP Eur J Cancer; 1995; 31A Suppl 7():S21-4. PubMed ID: 8562187 [No Abstract] [Full Text] [Related]
29. [Oncology for the general practioner--update 2007]. Cathomas R Praxis (Bern 1994); 2007 Dec; 96(50):1989-95. PubMed ID: 18179106 [TBL] [Abstract][Full Text] [Related]
31. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863 [No Abstract] [Full Text] [Related]
32. Is tailored therapy feasible in oncology? Gasparini G; Longo R; Torino F; Gattuso D; Morabito A; Toffoli G Crit Rev Oncol Hematol; 2006 Jan; 57(1):79-101. PubMed ID: 16337806 [TBL] [Abstract][Full Text] [Related]
33. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339 [TBL] [Abstract][Full Text] [Related]
34. The present and future of hematopoietic cytokines in clinical practice. George MJ Stem Cells; 1994; 12 Suppl 1():249-55. PubMed ID: 7696964 [TBL] [Abstract][Full Text] [Related]
35. Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Uray IP; Dmitrovsky E; Brown PH Semin Oncol; 2016 Feb; 43(1):49-64. PubMed ID: 26970124 [TBL] [Abstract][Full Text] [Related]
37. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer. Glackin CA Enzymes; 2018; 44():83-101. PubMed ID: 30360816 [TBL] [Abstract][Full Text] [Related]
38. Economic outcomes associated with the use of hematopoietic growth factors. Glaspy JA Oncology (Williston Park); 1995 Nov; 9(11 Suppl):93-105. PubMed ID: 8608062 [TBL] [Abstract][Full Text] [Related]
39. New oncology strategy: molecular targeting of cancer cells. Capriotti T Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169 [No Abstract] [Full Text] [Related]
40. [Intensive search for agents that knock out tumor growth]. Ostman A Lakartidningen; 2010 Apr 21-27; 107(16):1066-70. PubMed ID: 20476703 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]